Exchange: NYSE·Updated 07:51 PM EDT

DGX News

News
all
press releases
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
More News
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
TMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.
Zacks
Haystack MRD Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Haystack MRD Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials Haystack MRD Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer TrialsPR NewswireSECAUCUS, N.J., Oct. 1, 2026Test showed...
PR Newswire
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
Zacks
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026PR NewswireSECAUCUS, N.J., Sept. 22, 2026 SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a...
PR Newswire
Why Quest Diagnostics Holdings Stock Dropped Today
Key PointsMedicare and Medicaid have been overpaying Quest Diagnostics for years, says the government...
Nasdaq News: Markets
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
Zacks
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Zacks
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.read more...
Benzinga

Advertisement|Remove ads.